KYTHERA Biopharmaceuticals (FRA:KYT) Debt-to-Asset : 0.13 (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is KYTHERA Biopharmaceuticals Debt-to-Asset?

KYTHERA Biopharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2015 was €0.00 Mil. KYTHERA Biopharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2015 was €21.96 Mil. KYTHERA Biopharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2015 was €174.14 Mil. KYTHERA Biopharmaceuticals's debt to asset for the quarter that ended in Jun. 2015 was 0.13.

KYTHERA Biopharmaceuticals Debt-to-Asset Historical Data

The historical data trend for KYTHERA Biopharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KYTHERA Biopharmaceuticals Debt-to-Asset Chart

KYTHERA Biopharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Debt-to-Asset

0.04

0.07

0.27

KYTHERA Biopharmaceuticals Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15
Debt-to-Asset	Get a 7-Day Free Trial														0.22	0.24	0.27	0.13	0.13

Competitive Comparison of KYTHERA Biopharmaceuticals's Debt-to-Asset

For the Drug Manufacturers - General subindustry, KYTHERA Biopharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KYTHERA Biopharmaceuticals's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KYTHERA Biopharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where KYTHERA Biopharmaceuticals's Debt-to-Asset falls into.

KYTHERA Biopharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

KYTHERA Biopharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2014 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4.448	+	18.378)	/	83.878
	=	0.27

KYTHERA Biopharmaceuticals's Debt-to-Asset for the quarter that ended in Jun. 2015 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	21.959)	/	174.142
	=	0.13

KYTHERA Biopharmaceuticals (FRA:KYT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

KYTHERA Biopharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of KYTHERA Biopharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

KYTHERA Biopharmaceuticals (FRA:KYT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KYTHERA Biopharmaceuticals Inc (FRA:KYT) » Definitions » Debt-to-Asset

Traded in Other Exchanges

N/A

Address

Website

http://www.kytherabiopharma.com

KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.

KYTHERA Biopharmaceuticals (FRA:KYT) Headlines

No Headlines